| Literature DB >> 29553319 |
Chen Avni, Shmuel Stienlauf, Eyal Meltzer, Yechezkel Sidi, Eli Schwartz, Eyal Leshem.
Abstract
We characterized posttravel hospitalizations of citizens returning to Israel by summarizing the returning traveler hospitalization dataset of the national referral Center for Travel Medicine and Tropical Diseases at Sheba Medical Center in Israel. Of 722 hospitalizations, 181 (25%) infections were life-threatening; most would have been preventable by chemoprophylaxis and pretravel vaccination.Entities:
Keywords: Africa; Asia; Caribbean; Central America; Ethiopia; India; Israel; Plasmodium falciparum; Plasmodium vivax; Salmonella enterica serovar Paratyphi; Salmonella enterica serovar Typhi; South America; Staphylococcus; Thailand; chemoprophylaxis; dengue; enteric infections; hepatitis; leishmaniasis; leptospirosis; life-threatening; malaria; posttravel hospitalization; prophylaxis; schistosomiasis; vaccination; vector-borne infections
Mesh:
Year: 2018 PMID: 29553319 PMCID: PMC5875270 DOI: 10.3201/eid2404.171542
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Characteristics of travel-associated hospitalizations of citizens of Israel at Sheba Medical Center, Israel, 2004–2015*Category
| Category | Africa, n = 267 | Asia, n = 330 | South America, n = 43 | Central America/ Caribbean, n = 30 | North America/ Europe, n = 26 | Other,† n = 26 | Total, n = 722 |
|---|---|---|---|---|---|---|---|
| Patient characteristics | |||||||
| Sex | |||||||
| M | 226 (85) | 219 (66) | 28 (65) | 20 (67) | 21 (81) | 16 (62) | 530 (73) |
| F | 41 (15) | 111 (34) | 15 (35) | 10 (33) | 5 (19) | 10 (38) | 192 (27) |
| Age, median (IQR) | 41 (29–53) | 29 (24–43) | 24 (23–43) | 29 (27–46) | 55 (39–64) | 27 (23–41) | 33 (26–50) |
| Age ≥60 y | 37 (14) | 27 (8) | 4 (9) | 3 (10) | 8 (31) | 4 (15) | 83 (11) |
| Category of travelers | |||||||
| Tourism | 154 (58) | 313 (95) | 41 (95) | 29 (97) | 23 (88) | 26 (100) | 586 (81) |
| Business travelers | 93 (35) | 17 (5) | 2 (5) | 1 (3) | 3 (12) | 0 | 116 (16) |
| Visiting friends or relatives | 19 (7) | 1 (<1) | 0 | 0 | 0 | 0 | 20 (3) |
| Type of illness | |||||||
| Potentially preventable | 85 (32) | 25 (8) | 0 | 1 (3) | 0 | 1 (4) | 112 (16) |
| Febrile conditions | |||||||
| Malaria | |||||||
| 82 (30) | 4 (1) | 0 | 0 | 0 | 0 | 86 (12) | |
|
| 23 (9) | 7 (2) | 3 (7) | 0 | 0 | 3 (12) | 36 (5) |
|
| 8 (3) | 0 | 0 | 0 | 0 | 0 | 8 (1) |
|
| 7 (3) | 0 | 0 | 0 | 0 | 0 | 7 (<1) |
| Unidentified malaria | 6 (2) | 2 (<1) | 0 | 0 | 0 | 0 | 8 (1) |
| Dengue fever | 4 (1) | 59 (18) | 2 (5) | 8 (27) | 0 | 1 (4) | 74 (10) |
| Enteric fever | |||||||
| 2 (<1) | 19 (6) | 0 | 1 (3) | 0 | 1 (4) | 23 (3) | |
| 0 | 36 (11) | 0 | 0 | 0 | 0 | 36 (5) | |
| Leptospirosis | 1 (<1) | 18 (5) | 0 | 7 (23) | 1 (4) | 2 (8) | 29 (4) |
| Pneumonia | 10 (4) | 11 (3) | 0 | 1 (3) | 5 (19) | 1 (4) | 28 (4) |
| Febrile diarrheal diseases | 10 (4) | 5 (2) | 1 (2) | 0 | 2 (8) | 1 (4) | 19 (3) |
| Acute schistosomiasis | 16 (6) | 3 (<1) | 0 | 0 | 0 | 0 | 19 (3) |
| Influenza | 0 | 7 (2) | 0 | 0 | 0 | 1 (4) | 8 (1) |
| Epstein–Barr virus | 1 (<1) | 6 (2) | 1 (2) | 0 | 0 | 0 | 8 (1) |
| Cytomegalovirus | 4 (1) | 2 (<1) | 2 (5) | 0 | 0 | 0 | 8 (1) |
| Amebic liver abscess | 0 | 5 (2) | 0 | 0 | 0 | 2 (8) | 7 (<1) |
| Rickettsial diseases | 3 (1) | 3 (<1) | 0 | 0 | 0 | 0 | 6 (<1) |
| Upper respiratory tract infection | 4 (1) | 1 (<1) | 0 | 0 | 0 | 0 | 5 (<1) |
| Unspecified febrile illness | 34 (13) | 55 (17) | 7 (16) | 3 (10) | 6 (23) | 4 (15) | 109 (15) |
| Other febrile conditions | 15 (6) | 29 (9) | 8 (19) | 2 (7) | 3 (12) | 2 (8) | 59 (8) |
| Afebrile conditions | |||||||
| Afebrile diarrheal diseases | 5 (2) | 7 (2) | 2 (5) | 0 | 4 (15) | 0 | 18 (2) |
| Afebrile eosinophilia | 4 (1) | 6 (2) | 2 (5) | 1 (3) | 1 (4) | 2 (8) | 16 (2) |
| Skin disease | 7 (3) | 4 (1) | 2 (5) | 1 (3) | 0 | 0 | 14 (2) |
| Afebrile nondiarrheal GI illness | 3 (1) | 8 (2) | 2 (5) | 0 | 0 | 0 | 13 (2) |
| Viral hepatitis | 2 (<1) | 8 (2) | 0 | 2 (7) | 0 | 0 | 12 (2) |
| Leishmaniasis | 2 (<1) | 0 | 9 (21) | 0 | 0 | 0 | 11 (2) |
| Giardiasis | 0 | 4 (1) | 0 | 1 (3) | 0 | 0 | 5 (<1) |
| Other afebrile | 14 (5) | 21 (6) | 2 (5) | 3 (10) | 4 (15) | 6 (23) | 50 (7) |
| Outcome | |||||||
| Intensive care unit hospitalization | 4 (1) | 4 (1) | 0 | 0 | 2 (8) | 1 (4) | 11 (2) |
| Death | 1 (<1) | 1 (<1) | 0 | 0 | 0 | 0 | 2 (<1) |
*Values are no. (%) patients except as indicated. Further details are available in online Technical Appendix Table 1 (https://wwwnc.cdc.gov/EID/article/24/4/17-1542-Techapp1.pdf). GI, gastrointestinal; IQR, interquartile range. †Other comprises case-patients in Oceania (n = 6) and those for whom exact region of infection was undetermined (n = 26). ‡One patient returning from Asia with malaria had a coinfection with P. falciparum and P. vivax. In this table, we listed the patient under P. falciparum.
FigureTravel-associated hospitalizations of citizens of Israel at Sheba Medical Center, Israel, by country of disease acquisition (A), and estimated number of Israeli citizen entries to each country (B), 2004–2005. Data on Israeli citizen entries from the United Nations World Tourism Organization (). DRC, Democratic Republic of the Congo; PNG, Papua New Guinea.
Comparison of characteristics of travelers hospitalized for treatment of acute life-threatening tropical diseases and those with non–life-threatening illnesses, Sheba Medical Center, Israel, 2004–2015*
| Patient characteristics | Life-threatening illness,† n = 181 | Non–life-threatening illness, n = 541 | p value |
|---|---|---|---|
| Male sex | 145 (81) | 385 (71) | 0.02 |
| Age, median (IQR) | 33 (25–49) | 33 (25–50) | 0.62 |
| Elderly, age ≥60 y | 15 (8) | 68 (13) | 0.12 |
| Category of travelers | |||
| Tourism | 138 (76) | 448 (83) | 0.05 |
| Business travelers | 43 (24) | 73 (13) | <0.01 |
| Visiting friends or relatives | 0 (0) | 20 (3) | <0.01 |
| Continent of travel | |||
| Africa | 86 (48) | 181 (33) | <0.01 |
| Asia | 83 (46) | 247 (46) | 0.98 |
| South America | 0 | 43 (8) | <0.01 |
| Central America and Caribbean | 8 (4) | 22 (4) | 0.83 |
| North America and Europe | 1 (<1) | 25 (5) | <0.01 |
| Other‡ | 3 (2) | 23 (4) | 0.11 |
*Values are no. (%) patients except as indicated. IQR, interquartile range. †Life-threatening diseases (n = 181): P. falciparum (86), S. enterica ser. Paratyphi (36), leptospirosis (29), S. enterica ser. Typhi (23), rickettsial diseases (3), melioidosis (2), hantavirus (1), trypanosomiasis (1). ‡Other comprises Oceania (n = 6) and cases whose exact region of infection was undetermined (n = 26).